A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Recruiting
Phase 1
Phase 2
Interventional Study
Prostate Cancer
Prostate Cancer (Adenocarcinoma)
Fluorescence Imaging
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 90
- Sex
- Male
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 10 (estimated)
- Sponsor
- Antelope Surgical Solutions, Inc · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* suspected prostate cancer warranting standard of care multi-core prostate biopsy
Exclusion Criteria:
* Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
* Patients with pre-existing, impaired or abnormal he…
Contacts